| 000 | 01351 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250516013122.0 | ||
| 264 | 0 | _c20110609 | |
| 008 | 201106s 0 0 eng d | ||
| 022 | _a1365-2265 | ||
| 024 | 7 |
_a10.1111/j.1365-2265.2010.03939.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGrossmann, Mathis | |
| 245 | 0 | 0 |
_aAndrogen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? _h[electronic resource] |
| 260 |
_bClinical endocrinology _cMar 2011 |
||
| 300 |
_a289-93 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAndrogen Antagonists _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xadverse effects |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xdiagnosis |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xdiagnosis |
| 650 | 0 | 4 |
_aFractures, Bone _xprevention & control |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aZajac, Jeffrey D | |
| 773 | 0 |
_tClinical endocrinology _gvol. 74 _gno. 3 _gp. 289-93 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2265.2010.03939.x _zAvailable from publisher's website |
| 999 |
_c20388292 _d20388292 |
||